COVID-19 pandemic significantly impacted the DIAMOND study, leading to lower-than-anticipated enrolment and slower incidence of cardio-vascular events Independent study Executive Committee...

Abbas Hussain will take over as CEO of the Vifor Pharma Group on 16 August 2021 Succeeding Stefan Schulze, who has decided to step down and leave the company for personal reasons St. Gallen,...

Shareholders agreed to the Board of Directors’ recommendations for all proposed resolutions Election of Dr. Alexandre LeBeaut and Åsa Riisberg as Independent Directors Dividend of CHF 2.00 approved

Met primary efficacy endpoint of non-inferiority versus sevelamer carbonate Velphoro® effective in lowering and maintaining serum phosphorus level Safety profile of Velphoro® confirmed...

Topline data expected in the second half of 2021 St. Gallen, Switzerland, and Uniondale, NY, 29 April 2021 – Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of...